Last reviewed · How we verify
IMC-3G3
At a glance
| Generic name | IMC-3G3 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma (PHASE1, PHASE2)
- A Study of Olaratumab in Japanese Participants With Advanced Cancer (PHASE1)
- A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma (PHASE1)
- A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer (PHASE2)
- A Study of Olaratumab (IMC-3G3) in Prostate Cancer (PHASE2)
- A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme (PHASE2)
- A Study of Olaratumab in Soft Tissue Sarcoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMC-3G3 CI brief — competitive landscape report
- IMC-3G3 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI